Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Halfon

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Diabetes Care|July 1, 1988
Lack of detectable deleterious effects on metabolic control of daily fructose ingestion for 2 mo in NIDDM patientsC Grigoresco, S W Rizkalla, P Halfon, et al.
AIDS (London, England)|August 10, 2000
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt StudyJ Durant, P Clevenbergh, R Garraffo, et al.
Antiviral Therapy|June 10, 2000
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-upP Clevenbergh, J Durant, P Halfon, et al.
International Journal of Cancer|May 29, 2013
HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in FranceH Sancho-Garnier, C Tamalet, P Halfon, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 15, 2003
Transfusion-associated TT virus co-infection in patients with hepatitis C virus is associated with type II mixed cryoglobulinemia but not with B-cell non-Hodgkin lymphomaP Cacoub, E Rosenthal, V Gerolami, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2011
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 casesG Sebastiani, L Castera, P Halfon, et al.
The American Journal of Gastroenterology|May 17, 2002
Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary?C Renou, A Harafa, R Bouabdallah, et al.
Liver|July 21, 2000
Absence of hepatitis C genome in semen of infected men by polymerase chain reaction, branched DNA and in situ hybridizationE Debono, P Halfon, M Bourliere, et al.
Lancet (London, England)|July 7, 1999
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trialJ Durant, P Clevenbergh, P Halfon, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 28, 2002
High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patientsP. Clevenberg, J. Durant, P. Halfon, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Diabetes Care|July 1, 1988
Lack of detectable deleterious effects on metabolic control of daily fructose ingestion for 2 mo in NIDDM patientsC Grigoresco, S W Rizkalla, P Halfon, et al.
AIDS (London, England)|August 10, 2000
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt StudyJ Durant, P Clevenbergh, R Garraffo, et al.
Antiviral Therapy|June 10, 2000
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-upP Clevenbergh, J Durant, P Halfon, et al.
International Journal of Cancer|May 29, 2013
HPV self-sampling or the Pap-smear: a randomized study among cervical screening nonattenders from lower socioeconomic groups in FranceH Sancho-Garnier, C Tamalet, P Halfon, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 15, 2003
Transfusion-associated TT virus co-infection in patients with hepatitis C virus is associated with type II mixed cryoglobulinemia but not with B-cell non-Hodgkin lymphomaP Cacoub, E Rosenthal, V Gerolami, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2011
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 casesG Sebastiani, L Castera, P Halfon, et al.
The American Journal of Gastroenterology|May 17, 2002
Severe neutropenia and post-hepatitis C cirrhosis treatment: is interferon dose adaptation at once necessary?C Renou, A Harafa, R Bouabdallah, et al.
Liver|July 21, 2000
Absence of hepatitis C genome in semen of infected men by polymerase chain reaction, branched DNA and in situ hybridizationE Debono, P Halfon, M Bourliere, et al.
Lancet (London, England)|July 7, 1999
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trialJ Durant, P Clevenbergh, P Halfon, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 28, 2002
High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patientsP. Clevenberg, J. Durant, P. Halfon, et al.
Pageof 10